Ascendis Pharma A/S (ASND) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $237.98, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 1.8): -1.0; Consecutive earnings misses (2).
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency;... Read more
Hold if already holding. Not a fresh buy at $237.98, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 1.8): -1.0; Consecutive earnings misses (2). Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Ascendis Pharma A/S
Latest news
- ASND (Ascendis) edges higher post Q4 2025 results, with 98 percent revenue growth offsetting steep EPS miss. - Operating — Cổng thông tin điện tử Tỉnh Sơn La negative
- Ascendis Pharma slides as investors digest share-structure switch and convertible-note redemption - Quiver Quantitative — Quiver Quantitative negative
- Ascendis Pharma A/S (ASND) reports positive week 52 data from phase 2 new InsiGHTS trial - MSN — MSN positive
- Ascendis Pharma Calls Full Redemption of $575 Million 2028 Convertible Notes After Share Price Surge - TipRanks — TipRanks positive
- Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares - TipRanks — TipRanks neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $237.98, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 1.8): -1.0; Consecutive earnings misses (2). Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Maintain position. Not compelling to add more. Target $264.76 (+11.3%), stop $221.32 (−7.5%), A.R:R 1.2:1. Score 6.1/10, moderate confidence.
Take-profit target: $264.76 (+11.3% upside). Target $264.76 (+11.3%), stop $221.32 (−7.5%), A.R:R 1.2:1. Stop-loss: $221.32.
Leverage penalty (D/E 1.8): -1.0; Consecutive earnings misses (2).
Ascendis Pharma A/S trades at a P/E of 27.0 (forward 21.5). TrendMatrix value score: 4.9/10. Verdict: Hold.
24 analysts cover ASND with a consensus score of 4.4/5. Average price target: $294.
What does Ascendis Pharma A/S do?Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for...
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.